Abstract:Background and purpose:The prognostic factors for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel-based chemotherapy is still controversial. We aimed to evaluate the potential value of patient characteristics before the onset of chemotherapy to predict overall survival (OS) in Chinese patients. Methods:We retrospectively analyzed the data of 115 consecutive Chinese patients with mCRPC received docetaxel chemotherapy in our institution from Nov. 2005 to Sep. 2011. All 115 patients have bone metastasis, and 16 cases were simultaneously observed to have the presence of visceral metastasis including lung (9 cases), bladder (4 cases), liver (2 cases) and brain (1 case). The average cycles of chemotherapy was 6 ranging from 1 to 16. We retrospectively collected the variables including patient characteristics at diagnosis (age, serum PSA level, Gleason score) and characteristics before the start of chemotherapy (age, serum PSA level, complete blood count, hemoglobin (Hb) concentration , albumin concentration, bone and (or) visceral metastasis, Eastern Cooperative Oncology Group performance status (ECOG PS), cycles of chemotherapy and time to castration resistance). All laboratory analyses were performed in the same laboratory. Survival analysis was performed using Kaplan–Meier curves, and the differences in overall survival rates were assessed using the log-rank test. Only variables that were statistically significant in the univariate analysis (P<0.05) were included in the multivariate model. Results:The follow-up was performed until April 30, 2012, and median follow-up time was 45.0 months, ranging from 2.0 to 74.0 months. During the follow-up period, 87 of 115 patients (75.7%) died and the median OS for the entire cohort was 17.0 months, ranging from 2.0 to 46.0 months. The univariate analysis identified a total of 5 statistically significant predictors of OS: baseline serum PSA level, baseline Hb concentration, ECOG PS, cycles of chemotherapy, and time to castration resistance. Subsequent multivariate analysis reserved baseline Hb concentration and cycles of chemotherapy as independent prognostic factors for OS. Median OS for patients with baseline Hb concentration<110 g/L and ≥110 g/L were (12.0±2.2) months and (20.0±2.3) months, respectively (P=0.003). Median OS for patients with cycles of chemotherapy<6 and ≥6 were (12.0±1.2) months and (24.0±5.1) months, respectively (P<0.001). Conclusion:This retrospective analysis has demonstrated that baseline Hb concentration and cycles of chemotherapy could provide independent prognostic information of OS in Chinese patients with mCRPC treated with docetaxel. They can be used to optimize management of mCRPC.

The effect of docetaxel on immunological function of patients with metastatic breast cancer

A Meta-Analysis of Combination Therapy Versus Single-Agent Therapy in Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: Results from Nine Randomized Phase III Trials

[Predictive and Prognostic Value of Monitoring Lymphocyte Subsets in Peripheral Blood Before and after Chemotherapy in Patients with Metastatic Breast Cancer].

Immunomodulatory Effects of Docetaxel on Human Lymphocytes

Decrease of Peripheral Blood CD8+/CD28-suppressor T Cell Followed by Dentritic Cells Immunomodulation among Metastatic Breast Cancer Patients

P5-19-07: the Effects of ABCC2 and SLCO1B3 Single Nucleotide Polymorphisms on Docetaxel-Induced Leukopenia in Breast Cancer Patients.

Short-term Curative Effects of Docetaxel Combined with Capecitabine in Neoadjuvant Chemotherapy of Triple-negative Breast Cancer and Non Triple-negative Brest Cancer

Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel.

Changes And Significance Of Lymphocyte Subsets In Patients With Advanced Nsclc Before And After Endostar Combined Chemotherapy

Effects of chemotherapy on humoral immunity of patients with cancer

Factors influencing bone metastasis in HER-2 negative breast cancer and the efficacy of capecitabine plus docetaxel

Efficacy and Prognosis of First-Line Chemotherapy with Docetaxel Monotherapy or Docetaxel in Combination with Thiotepa in Treatment of Metastatic Breast Cancer

Antitumor and radiosensitizing effect of docetaxel on human hepatocellular carcinoma and its mechanisim in vivo

Impact of Chemotherapy on Circulating Lymphocyte Subsets in Lung Cancer Patients

Changes of CD4+, CD8+ and B cells in peripheral blood of breast cancer patients detected before and after surgery and following chemotherapy and their clinical significance

[Randomized Clinical Case-Control Trial for the Comparison of Docetaxel Plus Thiotepa Versus Docetaxel Plus Capecitabine in Patients with Metastatic Breast Cancer].

Clinical Value of Molecular Subtypes for Breast Cancer Predicting Therapeutic Effect and Prognosis of Dose Dense Docetaxel Neoadjuvant Chemotherapy

Prognostic Factors of Overall Survival for Chinese Patients with Metastatic Castration-Resistant prostate Cancer Treated with Docetaxel-Based Chemotherapy

Impact of Adjuvant Chemotherapy on the Survival of Patients with Estrogen Receptor ≥50 ％, Human Epidermal Growth Factor Receptor-2 Negative, Lymph Node Negative Breast Cancer

Elevated Level of Peripheral CD8+CD28− T Lymphocytes Are an Independent Predictor of Progression-Free Survival in Patients with Metastatic Breast Cancer During the Course of Chemotherapy

Effects of neoadjuvant chemotherapy combined with breast-conserving surgery on the breast cancer condition and immune and inflammatory indexes of patients with breast cancer